Related Experiment Video

Updated: Jun 1, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

[Avastin in the treatment of breast cancer]

K Petráková1

  • 1Klinika komplexní onkologické péce, Masaryküv onkologický Ostav, Brno. petrakova@mou.cz

Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti
|June 8, 2011
PubMed

Insights

Bevacizumab combined with taxane chemotherapy improves progression-free survival in metastatic breast cancer patients. This combination offers a potentially less toxic treatment option, especially for triple-negative breast cancer.

Area of Science:

  • Oncology
  • Pharmacology

Context:

  • Metastatic breast cancer treatment has evolved with new agents improving patient survival.
  • Chemotherapy is a cornerstone in managing metastatic breast cancer.
  • Bevacizumab, an antiangiogenic agent, shows efficacy across various solid tumors.

Purpose:

  • To evaluate the efficacy of combining taxanes with bevacizumab as a first-line treatment for metastatic breast cancer.

Summary:

  • Three randomized clinical trials (E2100, AVADO, RIBBON I) demonstrated the benefit of chemotherapy, specifically taxanes plus bevacizumab.
  • This combination significantly improved progression-free survival in all evaluated trials.
  • The addition of bevacizumab did not increase the known toxicities associated with taxanes.

Impact:

  • The combination of taxanes and bevacizumab represents a potent therapeutic option for metastatic breast cancer.
  • This regimen may be particularly beneficial for patients with triple-negative breast cancer.
  • It offers a potentially less toxic alternative to standard combination chemotherapy regimens.

More Related Videos

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring08:45

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Published on: November 13, 2012

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells09:24

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...